ISRCTN06158636 https://doi.org/10.1186/ISRCTN06158636

Tadalafil: effects on blood pressure and arterial stiffness in systolic hypertension

Submission date 30/09/2004	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol
Registration date 30/09/2004	**Overall study status** Completed	[_] Statistical analysis plan [_] Results
Last Edited 10/09/2008	**Condition category** Circulatory System	[_] Individual participant data [_] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Ian B Wilkinson

Contact details
Clinical Pharmacology Unit
Level 3, ACCI
Box 110
Addenbrooke's NHS Trust
Cambridge
United Kingdom
CB2 2QQ
+44 (0)1223 336806
ibw20@cam.ac.uk

Additional identifiers

Protocol serial number
N0544129338

Study information

Scientific Title

Study objectives
Does the selective phosphodiesterase-5 inhibitor tadalafil reduce arterial stiffness and blood pressure in systolic hypertension?

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Hypertension

Interventions
The project will assess the effects of a single dose of the selective phosphodiesterase-5 inhibitor tadalafil on arterial stiffness and blood pressure in patients with systolic hypertension. Subjects will visit the Vascular Research Clinics for a screening visit and two study visits and will receive either placebo or tadalafil on each study visit. Measurements of blood pressure and arterial stiffness will be made at baseline and at hourly intervals for four hours following administration of the drug or placebo.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Tadalafil

Primary outcome(s)
Not provided at time of registration

Key secondary outcome(s))
Not provided at time of registration

Completion date
10/08/2006

Eligibility

Key inclusion criteria
15 subjects over 18 years

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Lower age limit
18 years

Sex
All

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
11/08/2003

Date of final enrolment
10/08/2006

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Clinical Pharmacology Unit
Cambridge
United Kingdom
CB2 2QQ

Sponsor information

Organisation
Department of Health

Funder(s)

Funder type
Government

Funder Name
Cambridge Consortium - Addenbrooke's (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration